DAB389EGF (EGF-toxin fusion)
Bladder Cancer (non-muscle-invasive)
Pre-clinicalActive
Key Facts
About Aurora Oncology
Aurora Oncology is a pre-clinical, pre-revenue biotech advancing a novel, targeted approach to treating and diagnosing superficial bladder cancer. Its technology platform centers on EGFR-targeting, featuring a lead fusion toxin (DAB389EGF) with enhanced affinity and a complementary theranostic nanoparticle system for imaging and ablation. The company has secured significant non-dilutive funding through NIH SBIR grants and is affiliated with the Stanford and University of Colorado SPARK translational programs, positioning it to address a high-unmet-need market with outdated standard-of-care treatments.
View full company profile